These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22476191)

  • 1. Predictive factors for poor prognosis febrile neutropenia.
    Ahn S; Lee YS
    Curr Opin Oncol; 2012 Jul; 24(4):376-80. PubMed ID: 22476191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient therapy for febrile neutropenia.
    Innes H; Marshall E
    Curr Opin Oncol; 2007 Jul; 19(4):294-8. PubMed ID: 17545790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic factors for febrile neutropenia].
    Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
    Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
    Crawford J; Dale DC; Lyman GH
    Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cherif H; Johansson E; Björkholm M; Kalin M
    Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
    Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
    J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
    Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
    J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
    Ahn S; Lee YS; Lim KS; Lee JL
    Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of interleukin-5 and monocyte chemotactic protein-1 for bacteremia in children with febrile neutropenia.
    Aquino VM; Cost C; Gomez A; Bowers DC; Ramilo O; Ahmad N; Winick N; Leavey PJ
    J Pediatr Hematol Oncol; 2012 Aug; 34(6):e241-5. PubMed ID: 22584776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the risk of severe infection in children with chemotherapy-induced febrile neutropenia.
    Dubos F; Delebarre M; Martinot A
    Curr Opin Hematol; 2012 Jan; 19(1):39-43. PubMed ID: 22123661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
    Rondinelli PI; Ribeiro Kde C; de Camargo B
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):665-70. PubMed ID: 17023827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
    Chayakulkeeree M; Thamlikitkul V
    J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.
    El-Maghraby SM; Moneer MM; Ismail MM; Shalaby LM; El-Mahallawy HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):131-6. PubMed ID: 17356388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
    Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
    Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.